Sox2 modulates motility and enhances progression of colorectal cancer via the Rho-ROCK signaling pathway

作者：Junheng Zheng, Lixiao Xu, Yubin Pan, Shuyi Yu, Hongbo Wang, Derek Kennedy, Yan Zhang · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.21709 · 被引用次数：31 · 研究领域：Cancer Cells and Metastasis、Wnt/β-catenin signaling in development and cancer、FOXO transcription factor regulation

// Junheng Zheng 1, 2, * , Lixiao Xu 1, * , Yubin Pan 1, 2 , Shuyi Yu 1, 2 , Hongbo Wang 3 , Derek Kennedy 2, 4 and Yan Zhang 1, 2 1 Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China 2 Sun Yat-sen University-Griffith University Joint Laboratory for Drug Discovery, Guangzhou, China 3 Sun Yat-sen University Cancer Center, Guangzhou, China 4 Griffith Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia * These authors have contributed equally to this work Correspondence to: Yan Zhang, email: zhang39@mail.sysu.edu.cn Keywords: Sox2; colorectal cancer; cancer stem cell; motility; ROCK Received: March 31, 2017     Accepted: August 23, 2017     Published: October 10, 2017 ABSTRACT Sox2 (Sry-box2) is essential for a variety of stem cells and is also expressed in colorectal cancer (CRC). However, the underlying mechanism by which Sox2 enhances CRC progression remains unclear. In the present study, we show that elevated Sox2 expression is significantly correlated with poor clinical prognosis. CRC is phenotypically heterogeneous, and harbors several subtypes of cancer cells. Elevated Sox2 expression was always detected in rounded-shape cells, which co-located to poorly differentiated regions, the invasive frontier and metastatic lesions. Knockdown of Sox2 in CRC cells not only decreased the number of ro...